<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Fluocinolone (topical): Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Fluocinolone (topical): Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Fluocinolone (topical): Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="9130" href="/d/html/9130.html" rel="external">see "Fluocinolone (topical): Drug information"</a> and <a class="drug drug_patient" data-topicid="11683" href="/d/html/11683.html" rel="external">see "Fluocinolone (topical): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F8097444"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Capex;</li>
<li>Derma-Smoothe/FS Body;</li>
<li>Derma-Smoothe/FS Scalp;</li>
<li>Synalar;</li>
<li>Synalar (Cream) [DSC];</li>
<li>Synalar (Ointment) [DSC];</li>
<li>Synalar TS [DSC]</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52869153"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Derma-Smoothe/FS;</li>
<li>Fluoderm [DSC];</li>
<li>Synalar;</li>
<li>Synalar Mild</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F10501531"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Adrenal Corticosteroid</span>;</li>
<li>
<span class="list-set-name">Anti-inflammatory Agent</span>;</li>
<li>
<span class="list-set-name">Corticosteroid, Topical</span>;</li>
<li>
<span class="list-set-name">Glucocorticoid</span></li></ul></div>
<div class="block dop drugH1Div" id="F8100670"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Dosage should be based on severity of disease and patient response; use smallest amount for shortest period of time to avoid HPA axis suppression. Therapy should be discontinued when control is achieved.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d8ecd230-ce3b-46da-85b5-ab9bafc77949">Atopic dermatitis, moderate to severe</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Atopic dermatitis, moderate to severe:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Derma-Smoothe/FS body oil (0.01%): Infants ≥3 months, Children, and Adolescents: Topical: Moisten skin; apply a thin film to affected area twice daily; do not use for longer than 4 weeks</p>
<p style="text-indent:-2em;margin-left:4em;">Derma-Smoothe/FS scalp oil (0.01%): Limited data available: Children ≥2 years and Adolescents: Topical: Apply a thin film to affected area twice daily; do not use longer than 4 weeks</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7fcdd7c2-fcea-459c-b474-e68d6e2cb01d">Corticosteroid-responsive dermatoses</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Corticosteroid-responsive dermatoses:</b> Synalar cream (0.025%), ointment (0.025%), topical solution (0.01%): Children and Adolescents: Topical: Apply thin layer 2 to 4 times daily to affected area; may use occlusive dressings to manage psoriasis or recalcitrant conditions</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51111052"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block dohp drugH1Div" id="F51111053"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doa drugH1Div" id="F8100671"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="9130" href="/d/html/9130.html" rel="external">see "Fluocinolone (topical): Drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Note: </b>Dosage should be based on severity of disease and patient response; use smallest amount for shortest period of time. Therapy should be discontinued when control is achieved.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c67e9e2b-6dad-418d-9ecc-84f4de0f5978">Atopic dermatitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Atopic dermatitis:</b>
<b>Topical:</b> Body oil: Apply thin film to affected area 3 times daily</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7fcdd7c2-fcea-459c-b474-e68d6e2cb01d">Corticosteroid-responsive dermatoses</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Corticosteroid-responsive dermatoses:</b>
<b>Topical:</b> Cream, ointment, solution: Apply a thin layer to affected area 2 to 4 times daily; may use occlusive dressings to manage psoriasis or recalcitrant conditions</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d7c83a95-5615-4742-bc5b-d4be859f010b">Scalp psoriasis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Scalp psoriasis:</b>
<b>Topical:</b> Scalp oil: Apply a thin film onto scalp and massage thoroughly into wet or dampened hair/scalp; cover with shower cap. Leave on overnight (or for at least 4 hours). Remove by washing hair with shampoo and rinsing thoroughly.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5b2f1229-5d46-48b6-9dce-b46d78b49425">Seborrheic dermatitis of the scalp</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Seborrheic dermatitis of the scalp:</b>
<b>Topical:</b> Shampoo: Apply no more than 1 ounce to scalp once daily; work into lather and allow to remain on scalp for ~5 minutes. Remove from hair and scalp by rinsing thoroughly with water.</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50990878"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doha drugH1Div" id="F50988171"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block adr drugH1Div" id="F8097485"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Reported adverse reactions are for body or scalp oil in infants and children.</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Acneiform eruptions, atopic dermatitis (secondary), burning sensation of skin, eczema, erythema of skin, folliculitis, hyperkeratosis (keratosis pilaris), hyperpigmentation, hypopigmentation, molluscum contagiosum, papule of skin, pruritus, scalp pustules, skin irritation, skin rash, taut and shiny skin, telangiectasia</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Diarrhea, vomiting</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Abscess, herpes simplex infection (facial)</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Otic infection</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Cough, nasopharyngitis, rhinorrhea, upper respiratory tract infection</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever</p></div>
<div class="block coi drugH1Div" id="F8097474"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to fluocinolone or any component of the formulation</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in US labeling): Viral (eg, herpes, varicella) lesions of the skin; bacterial or fungal skin infections; parasitic infections; skin manifestations relating to tuberculosis or syphilis; eruptions following vaccinations; application to the eye</p></div>
<div class="block war drugH1Div" id="F8097475"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Adrenal suppression: May cause hypercortisolism or suppression of hypothalamic-pituitary-adrenal (HPA) axis, particularly in younger children or in patients receiving high doses for prolonged periods. HPA axis suppression may lead to adrenal crisis.</p>
<p style="text-indent:-2em;margin-left:4em;">• Contact dermatitis: Allergic contact dermatitis can occur, it is usually diagnosed by failure to heal rather than clinical exacerbation.</p>
<p style="text-indent:-2em;margin-left:4em;">• Kaposi sarcoma: Prolonged treatment with corticosteroids has been associated with the development of Kaposi sarcoma (case reports); if noted, discontinuation of therapy should be considered (Goedert 2002).</p>
<p style="text-indent:-2em;margin-left:4em;">• Local effects: Local adverse reactions may occur (eg, skin atrophy, striae, telangiectasias, burning, itching, irritation, dryness, folliculitis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, secondary infection miliaria); may be irreversible. Local adverse reactions are more likely to occur with occlusive and/or prolonged use. If irritation develops, discontinued use and institute appropriate therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Skin infections: Concomitant skin infections may be present or develop during therapy; discontinue if dermatological infection persists despite appropriate antimicrobial therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Systemic effects: Topical corticosteroids may be absorbed percutaneously. Absorption of topical corticosteroids may cause manifestations of Cushing syndrome, hyperglycemia, or glycosuria. Absorption is increased by the use of occlusive dressings, application to denuded skin, or application to large surface areas.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Pediatric: Children may absorb proportionally larger amounts after topical application and may be more prone to systemic effects. HPA axis suppression, intracranial hypertension, and Cushing syndrome have been reported in children receiving topical corticosteroids. Prolonged use may affect growth velocity; growth should be routinely monitored in pediatric patients.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Peanut oil: Derma-Smoothe/FS products may contain peanut oil; use caution in peanut-sensitive individuals.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Not for oral, ophthalmic, or intravaginal use; do not apply to the face, axillae, groin, or diaper area unless directed by health care provider. Use the least amount needed to cover the affected area; discontinue when control is achieved. If improvement is not seen within 2 weeks, reassess.</p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Shampoo: Has not been proven to be effective in corticosteroid responsive dermatoses other than seborrheic dermatitis of the scalp.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878736"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Topical corticosteroids may be absorbed percutaneously. The extent of absorption is dependent on several factors, including epidermal integrity (intact vs abraded skin), formulation, age of the patient, prolonged duration of use, and the use of occlusive dressings. Percutaneous absorption of topical steroids is increased in neonates (especially preterm neonates), infants, and young children. Hypothalamic-pituitary-adrenal (HPA) suppression may occur, particularly in younger children or in patients receiving high doses for prolonged periods; acute adrenal insufficiency (adrenal crisis) may occur with abrupt withdrawal after long-term therapy or with stress. Infants and small children may be more susceptible to HPA axis suppression or other systemic toxicities due to larger skin surface area to body mass ratio; use with caution in pediatric patients. </p>
<p style="text-indent:0em;margin-top:2em;">Some dosage forms may contain propylene glycol; in neonates large amounts of propylene glycol delivered orally, intravenously (eg, &gt;3,000 mg/day), or topically have been associated with potentially fatal toxicities which can include metabolic acidosis, seizures, renal failure, and CNS depression; toxicities have also been reported in children and adults including hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP, 1997; Shehab, 2009).</p></div>
<div class="block foc drugH1Div" id="F8100716"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Cream, External, as acetonide: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Synalar: 0.025% (120 g) [contains cetyl alcohol, edetate (edta) disodium, methylparaben, propylene glycol, propylparaben]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.01% (15 g, 60 g); 0.025% (15 g, 60 g)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Kit, External, as acetonide: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Synalar (Cream): 0.025% [DSC] [contains cetyl alcohol, edetate (edta) disodium, methylparaben, propylene glycol, propylparaben]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Synalar (Ointment): 0.025% [DSC]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Synalar TS: 0.01% [DSC] [contains propylene glycol]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Oil, External, as acetonide: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Derma-Smoothe/FS Body: 0.01% (118.28 mL) [contains isopropyl alcohol, peanut oil]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Derma-Smoothe/FS Scalp: 0.01% (20 mL [DSC], 118.28 mL) [contains isopropyl alcohol, peanut oil]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.01% (118.28 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Ointment, External, as acetonide: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Synalar: 0.025% (120 g)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.025% (15 g, 60 g)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Shampoo, External, as acetonide: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Capex: 0.01% (120 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, External, as acetonide: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Synalar: 0.01% (60 mL [DSC], 90 mL [DSC]) [contains propylene glycol]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.01% (60 mL)</p></div>
<div class="block geq drugH1Div" id="F8097456"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">May be product dependent</p></div>
<div class="block fee drugH1Div" id="F8100718"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Cream</b> (Fluocinolone Acetonide External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.01% (per gram): $2.99</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.025% (per gram): $2.99</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Cream</b> (Synalar External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.025% (per gram): $6.27</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Oil</b> (Derma-Smoothe/FS Body External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.01% (per mL): $0.37</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Oil</b> (Derma-Smoothe/FS Scalp External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.01% (per mL): $0.35</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Oil</b> (Fluocinolone Acetonide Body External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.01% (per mL): $0.37 - $1.87</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Oil</b> (Fluocinolone Acetonide Scalp External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.01% (per mL): $0.94 - $1.89</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Ointment</b> (Fluocinolone Acetonide External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.025% (per gram): $2.25 - $2.26</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Ointment</b> (Synalar External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.025% (per gram): $6.27</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Shampoo</b> (Capex External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.01% (per mL): $3.82</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Fluocinolone Acetonide External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.01% (per mL): $0.66 - $3.13</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52869154"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Cream, External, as acetonide: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Fluoderm: 0.01% ([DSC]); 0.025% ([DSC])</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Oil, External: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Derma-Smoothe/FS: 0.01% (118 mL, 120 mL, 355 mL) [contains alcohol, usp, peanut oil]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Ointment, External: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Synalar Mild: 0.01% (60 g)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Ointment, External, as acetonide: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Fluoderm: 0.025% ([DSC])</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Synalar: 0.025% (60 g)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, External, as acetonide: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Synalar: 0.01% ([DSC])</p></div>
<div class="block adip drugH1Div" id="F53569955"><span class="drugH1">Additional Information</span>
<p style="text-indent:0em;display:inline">Considered a moderate-potency steroid (Derma-Smoothe/FS and Capex shampoo are considered to be low to medium potency); Derma-Smoothe/FS is made with 48% refined peanut oil, NF (peanut protein is &lt;0.5 ppm)</p></div>
<div class="block admp drugH1Div" id="F52614347"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Synalar cream, ointment, topical solution: Apply sparingly in a thin film; rub in lightly. In hairy sites, the hair should be parted to allow direct contact with the lesion.</p>
<p style="text-indent:-2em;margin-left:2em;">Derma-Smoothe/FS (body oil, scalp oil): Do not apply to face or diaper area; avoid application to intertriginous areas (may increase local adverse effects)</p></div>
<div class="block adm drugH1Div" id="F8100675"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">Topical: Not for oral, ophthalmic, or intravaginal use; do not apply to the face, axillae, or groin unless directed by healthcare provider.</p>
<p style="text-indent:-2em;margin-left:2em;">Body oil: Apply the least amount necessary to cover the affected area; do not apply to intertriginous areas.</p>
<p style="text-indent:-2em;margin-left:2em;">Cream, ointment, topical solution: Apply sparingly in a thin film; rub in lightly. In hairy sites, the hair should be parted to allow direct contact with the lesion. Occlusive dressings may be helpful in managing psoriasis or recalcitrant conditions, but should not be used if an infection develops.</p>
<p style="text-indent:-2em;margin-left:2em;">Shampoo: Shake well before use; do not bandage, wrap, or cover treated scalp area unless directed by healthcare provider.</p></div>
<div class="block sts drugH1Div" id="F8097502"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:-2em;margin-left:2em;">Body oil, scalp oil, shampoo: Store between 20°C and 25°C (68°F and 77°F); excursions are permitted to 15°C to 30°C (59°F to 86°F). Discard shampoo after 2 months.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Cream, ointment, topical solution: Store between 15°C and 25°C (59°F and 77°F); avoid freezing and excessive heat above 40°C (104°F).</p></div>
<div class="block usep drugH1Div" id="F53570520"><span class="drugH1">Use</span>
<p style="text-indent:-2em;margin-left:2em;">Body Oil (0.01%) (Derma-Smoothe/FS): Treatment of moderate to severe atopic dermatitis (FDA approved in pediatric patients ≥3 months); treatment of atopic dermatitis (FDA approved in adults)  </p>
<p style="text-indent:-2em;margin-left:2em;">Cream (0.025%), Ointment (0.025%), Topical solution (0.01%) (Synalar):  Relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses (FDA approved in pediatric patients [age not specified] and adults)  </p>
<p style="text-indent:-2em;margin-left:2em;">Scalp Oil (0.01%) (Derma-Smoothe/FS): Treatment of  psoriasis of the scalp (FDA approved in adults); has also been used for moderate to severe atopic dermatitis on the scalp </p>
<p style="text-indent:-2em;margin-left:2em;">Shampoo (0.01%) (Capex): Treatment of seborrheic dermatitis of the scalp (FDA approved in adults)</p></div>
<div class="block mst drugH1Div" id="F8097421"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Capex may be confused with Kapidex [DSC]</p>
<p style="text-indent:-2em;margin-left:4em;">Fluocinolone may be confused with fluocinonide</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Pediatric patients: High-risk medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">KIDs List: Medium, high, and very high potency topical corticosteroids, when used in neonates and infants &lt;1 year of age for diaper dermatitis, are identified on the Key Potentially Inappropriate Drugs in Pediatrics (KIDs) list; use should be avoided due to risk of adrenal suppression; systemic absorption is higher in pediatric patients than adults (strong recommendation; low quality of evidence) (PPA [Meyers 2020]).</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299349"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F8097493"><span class="drugH1">Drug Interactions</span>
<br/><br/><div class="clear"></div><p style="text-indent:0em;display:inline">There are no known significant interactions.</p></div>
<div class="block rep_considerations drugH1Div" id="F56223284"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;display:inline">Topical corticosteroids may be used for the treatment of corticosteroid-responsive dermatosis, such as atopic dermatitis, in patients planning a pregnancy (Vestergaard 2019).</p></div>
<div class="block pri drugH1Div" id="F8097470"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Systemic bioavailability of topical corticosteroids is variable (integrity of skin, use of occlusion, etc) and may be further influenced by trimester of pregnancy (Chi 2017). In general, the use of topical corticosteroids is not associated with a significant risk of adverse pregnancy outcomes. However, there may be an increased risk of low-birth-weight infants following maternal use of potent or very potent topical products, especially in high doses, although this risk is likely to be low (Andersson 2021; Chi 2015; Chi 2017).</p>
<p style="text-indent:0em;margin-top:2em;">When first-line treatments, such as emollients, are insufficient, topical corticosteroids may be used for the treatment of atopic dermatitis in pregnant patients (Vestergaard 2019). Topical corticosteroids are classified by potency; the medication and formulation (eg, cream, gel, and/or salt form) contribute to the potency classification (Oakley 2021; Stacey 2021; Tadicherla 2009). In general, use of the least potent product in limited amounts is recommended during pregnancy. Mild to moderate potency corticosteroids are preferred; potent to very potent topical corticosteroids should only be used as alternative therapy in limited amounts under obstetrical care. Pregnant patients should avoid application of topical corticosteroids to areas with high percutaneous absorption (eg, arm pit, skin folds, vulva) (Chi 2017), and caution should be used when applying to areas prone to striae formation (eg, abdomen, breast, thighs) (Vestergaard 2019).</p></div>
<div class="block mopp drugH1Div" id="F53570521"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Growth in pediatric patients; assess HPA axis suppression (eg, ACTH stimulation test, morning plasma cortisol test, urinary free cortisol test) </p></div>
<div class="block pha drugH1Div" id="F8100660"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Topical corticosteroids have anti-inflammatory, antipruritic, and vasoconstrictive properties. May depress the formation, release, and activity of endogenous chemical mediators of inflammation (kinins, histamine, liposomal enzymes, prostaglandins) through the induction of phospholipase A<sub>2</sub> inhibitory proteins (lipocortins) and sequential inhibition of the release of arachidonic acid.  Fluocinolone has low to intermediate range potency (dosage-form dependent).</p></div>
<div class="block phk drugH1Div" id="F8100662"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Absorption: Dependent on formulation, amount applied, nature of skin at application site; may be increased with inflammation or occlusion </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Metabolism: Hepatic </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Excretion: Primarily urine; bile </p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F10961973"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Dermolar | Supricort | Synalar</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Flulone</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Synalar</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Alor | Cinoderm | Dermidex | Skinalar</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Synalar</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Abricort | Flucinar | Synalar</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Dermobet | Synalar</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Adermina</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Fluocinolone | Fluocinolone acet</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Dermacril | Glencort | Synalar simple</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Flucinar | Gelargin | Synalar</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Flucinar | Jellin | Jellisoft</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Derma cort | Fluocinol</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Flucinar | Sinoderm | Synaflan | Synalar</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Tretoflamin</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Alvadermo | Co fluocin | Fluocid | Fluodermo</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Synalar | Synandone</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Synalar | Synalar gras</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Synalar | Synandone</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Synalar simple</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Aplosyn | Bf-Fluocinolone | Cino | Cinotec | Coderma | Fluasyn | Fluciderm | Flucortderm | Fluocin | Fluocina F | Fluocinolone | Fluoderm | Fluosyn | Fluotopic | Natiderm | Qualicinone | Synaderm | Synalar | Synalone | Synfulin | Uni-Fluocin</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Flucinar | Synalar</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Bravoderm | Cinolon | Dermasolon | Esinol | Inoderm | Kalcinol | Licosolon | Synalar | Synarcus</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Synalar</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Dermalar</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Emderm | Flucin | Fluclear | Flucocin | Flucort | Flucort h | Fluderm | Pelliwash | Sebowash | Supricort</span>;</li>
<li>
<span class="countryCode">(IQ)</span> <span class="country">Iraq</span><span class="countrySeparator">: </span><span class="drugName">Fluosam | Proctodain</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Atoactive | Cortamide | Dermolin | Doricum semplice | Fluocit | Fluomix | Fluovitef | Locafluo | Localyn | Omniderm | Sterolone | Ultraderm</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Flocinal | Petralar | Synalar</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Coriphate | Esalan f | Flucort | Flupollon aventis | Flupollon mayado | Fluvean | Glycobase mayado | Murukonin mita | Polysiral</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Florin | Flumort | Flutran | Furuciron | Synalar</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Synalar</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Fluocinolone | Isoderma | Seboclean | Sebowash | Synalar</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Abricort | Flucinar | Gelargin | Synaflan | Synaflani | Synalar</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Synalar</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Abricort | Flucinar | Flucort | Fluocinolon ac | Gelargin | Synaflan | Synaflani | Synalar | Ultraderm</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Synalar</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Colurene | Cortifung S | Cortilona | Cremisona | Dermalar | Dilarmine | Flucin | Flumicin | Fluocinolon gi | Fluocinolona | Fluocinolona Antibioticos | Fluocinolona Ferring | Fluocinolona gi | Fluocinolona gi ar | Fluocinolona Lilly | Fusalar | Lonason | Luzolona-s | Naflucen | Synalar s | Synalar simple</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Fluciderm | Fluocinolone | Fluonid | Lycort | Supricort | Synalar</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Synalar</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Synalar</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Dermoflam | Supricort | Synalar simple</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Aplosyn | Flozet | Flucin | Synalar | Syntopic</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Derma smooth | Dermalar | Flucin | Fucinol | Synalar</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Flucinar | Synalar</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Capex | Derma-smoothe/fs | Fluocinolone acetate | Fluonid | Synalar | Synemol</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Fluocinolona | Synalar</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Dermolar</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Flucinar | Fluocinolon acetonid laropharm</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Abricort | Flucinar | Flucort | Flunolon | Sinaflan | Sinaflan akrikhin | Sinaflana | Sinoderm | Synaflan | Synalar</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Dermolar | Petralar | Synalar</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Synalar</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Fluciderm | Flunolone v | Fluocinolone | Fluosyn | Supricort | Synalar</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Fluacet | Synalar</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Flucinar | Gelargin | Synalar</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Cervicum | Fluciderm | Fluocinar | Fluonid | Fluostar | Fulone | Supralan | Synalar | Synolone</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Flucin | Flucort | Flunolone | Fluo A | Fluocinolone | Fluogor | Fluosyn | Flusonlen | Franolon | Fupaokan | Futocan | Lesumin | Paracort | Patroncort | Solunim | Sulikon | Wantacort</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Flucar | Fluciderm | Flucinar | Sinaflan | Sinoderm | Synaflan | Synaflan phytopharm</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Synalar | Synalar simple</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Fluquinol simple | Neoflu | Neosynalar simple</span>;</li>
<li>
<span class="countryCode">(VN)</span> <span class="country">Viet Nam</span><span class="countrySeparator">: </span><span class="drugName">Flucinar | Fluopas | Hatafluna | Morcina | Traphalucin</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Cortoderm | Cortoderm-c | Synalar</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Synalar</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>American Academy of Pediatrics Committee on Drugs. "Inactive" ingredients in pharmaceutical products: update (subject review). <i>Pediatrics</i>. 1997;99(2):268-278.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluocinolone-topical-pediatric-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33950165">
<a name="33950165"></a>Andersson NW, Skov L, Andersen JT. Evaluation of topical corticosteroid use in pregnancy and risk of newborns being small for gestational age and having low birth weight. <i>JAMA Dermatol</i>. 2021;157(7):788-795. doi:10.1001/jamadermatol.2021.1090<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluocinolone-topical-pediatric-drug-information/abstract-text/33950165/pubmed" id="33950165" target="_blank">33950165</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24528912">
<a name="24528912"></a>Butler DC, Heller MM, Murase JE. Safety of dermatologic medications in pregnancy and lactation: Part II. Lactation. <i>J Am Acad Dermatol</i>. 2014;70(3):417.e1-10; quiz 427. doi:10.1016/j.jaad.2013.09.009<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluocinolone-topical-pediatric-drug-information/abstract-text/24528912/pubmed" id="24528912" target="_blank">24528912</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Capex shampoo (fluocinolone acetonide) [prescribing information]. Fort Worth, TX: Galderma Laboratories; December 2015.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26497573">
<a name="26497573"></a>Chi CC, Wang SH, Wojnarowska F, Kirtschig G, Davies E, Bennett C. Safety of topical corticosteroids in pregnancy.<i> Cochrane Database Syst Rev</i>. 2015;(10):CD007346. doi:10.1002/14651858.CD007346.pub3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluocinolone-topical-pediatric-drug-information/abstract-text/26497573/pubmed" id="26497573" target="_blank">26497573</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28233354">
<a name="28233354"></a>Chi CC, Kirtschig G, Aberer W, et al. Updated evidence-based (S2e) European Dermatology Forum guideline on topical corticosteroids in pregnancy. <i>J Eur Acad Dermatol</i> Venereol. 2017;31(5):761-773. doi:10.1111/jdv.14101<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluocinolone-topical-pediatric-drug-information/abstract-text/28233354/pubmed" id="28233354" target="_blank">28233354</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Derma-Smoothe/FS body oil (fluocinolone acetonide) [prescribing information]. Manasquan, NJ: Royal Pharmaceuticals; June 2013.</div>
</li>
<li>
<div class="reference">
                  Derma-Smoothe/FS scalp oil (fluocinolone acetonide) [prescribing information]. Manasquan, NJ: Royal Pharmaceuticals; June 2013.</div>
</li>
<li>
<div class="reference">
                  Derma-Smoothe/FS topical oil (fluocinolone acetonide) [product monograph]. Mississauga, Ontario, Canada: Hill Dermaceuticals; May 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32738429">
<a name="32738429"></a>Elmets CA, Korman NJ, Prater EF, et al. Joint AAD-NPF Guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures. <i>J Am Acad Dermatol</i>. 2021;84(2):432-470. doi:10.1016/j.jaad.2020.07.087<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluocinolone-topical-pediatric-drug-information/abstract-text/32738429/pubmed" id="32738429" target="_blank">32738429</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12441327">
<a name="12441327"></a>Goedert JJ, Vitale F, Lauria C, et al. Risk factors for classical Kaposi's sarcoma. <i>J Natl Cancer Inst.</i> 2002;94(22):1712-1718.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluocinolone-topical-pediatric-drug-information/abstract-text/12441327/pubmed" id="12441327" target="_blank">12441327</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16677965">
<a name="16677965"></a>Leachman SA, Reed BR. The use of dermatologic drugs in pregnancy and lactation. <i>Dermatol Clin</i>. 2006;24(2):167-197, vi. doi:10.1016/j.det.2006.01.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluocinolone-topical-pediatric-drug-information/abstract-text/16677965/pubmed" id="16677965" target="_blank">16677965</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32265601">
<a name="32265601"></a>Meyers RS, Thackray J, Matson KL, et al. <i>K</i>ey Potentially <i>I</i>nappropriate <i>D</i>rugs in Pediatrics: The KIDs List. <i>J Pediatr Pharmacol Ther</i>. 2020;25(3):175-191.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluocinolone-topical-pediatric-drug-information/abstract-text/32265601/pubmed" id="32265601" target="_blank">32265601</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33108015">
<a name="33108015"></a>Oakley R, Arents BWM, Lawton S, Danby S, Surber C. Topical corticosteroid vehicle composition and implications for clinical practice. <i>Clin Exp Dermatol</i>. 2021;46(2):259-269. doi:10.1111/ced.14473<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluocinolone-topical-pediatric-drug-information/abstract-text/33108015/pubmed" id="33108015" target="_blank">33108015</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19188870">
<a name="19188870"></a>Shehab N, Lewis CL, Streetman DD, Donn SM. Exposure to the pharmaceutical excipients benzyl alcohol and propylene glycol among critically ill neonates. <i>Pediatr Crit Care Med</i>. 2009;10(2):256-259.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluocinolone-topical-pediatric-drug-information/abstract-text/19188870/pubmed" id="19188870" target="_blank">19188870</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33719380">
<a name="33719380"></a>Stacey SK, McEleney M. Topical corticosteroids: choice and application. <i>Am Fam Physician</i>. 2021;103(6):337-343.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluocinolone-topical-pediatric-drug-information/abstract-text/33719380/pubmed" id="33719380" target="_blank">33719380</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Synalar cream (fluocinolone acetonide) [prescribing information]. Fairfield, NJ: Medimetriks Pharmaceuticals; November 2016.</div>
</li>
<li>
<div class="reference">
                  Synalar ointment (fluocinolone acetonide) [prescribing information]. Fairfield, NJ: Medimetriks Pharmaceuticals; November 2016.</div>
</li>
<li>
<div class="reference">
                  Synalar ointment (fluocinolone acetonide) [product monograph]. Laval, Quebec, Canada: Bausch Health, Canada Inc; June 2021.</div>
</li>
<li>
<div class="reference">
                  Synalar ointment and solution (fluocinolone acetonide) [product monograph]. Laval, Quebec, Canada: Bausch Health, Canada; October 2020.</div>
</li>
<li>
<div class="reference">
                  Synalar topical solution (fluocinolone acetonide) [prescribing information]. Fairfield, NJ: Medimetriks Pharmaceuticals Inc; June 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20027937">
<a name="20027937"></a>Tadicherla S, Ross K, Shenefelt PD, Fenske NA. Topical corticosteroids in dermatology. <i>J Drugs Dermatol</i>. 2009;8(12):1093-1105.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluocinolone-topical-pediatric-drug-information/abstract-text/20027937/pubmed" id="20027937" target="_blank">20027937</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31231864">
<a name="31231864"></a>Vestergaard C, Wollenberg A, Barbarot S, et al. European task force on atopic dermatitis position paper: treatment of parental atopic dermatitis during preconception, pregnancy and lactation period.<i> J Eur Acad Dermatol Venereol</i>. 2019;33(9):1644-1659. doi:10.1111/jdv.15709<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluocinolone-topical-pediatric-drug-information/abstract-text/31231864/pubmed" id="31231864" target="_blank">31231864</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the eleventh WHO model list of essential drugs. 2002. https://apps.who.int/iris/handle/10665/62435
                  </div>
</li></ol></div><div id="topicVersionRevision">Topic 15987 Version 271.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
